- Home
- WFF vs TCRX Comparison
WFF vs TCRX Comparison
Compare WFF & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WFF
- TCRX
- Stock Information
- Founded
- WFF 1984
- TCRX 2018
- Country
- WFF Malaysia
- TCRX United States
- Employees
- WFF N/A
- TCRX N/A
- Industry
- WFF Miscellaneous manufacturing industries
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- WFF Consumer Discretionary
- TCRX Health Care
- Exchange
- WFF Nasdaq
- TCRX Nasdaq
- Market Cap
- WFF 155.9M
- TCRX 86.6M
- IPO Year
- WFF 2025
- TCRX 2021
- Fundamental
- Price
- WFF $6.05
- TCRX $1.68
- Analyst Decision
- WFF
- TCRX Strong Buy
- Analyst Count
- WFF 0
- TCRX 6
- Target Price
- WFF N/A
- TCRX $9.50
- AVG Volume (30 Days)
- WFF 471.7K
- TCRX 444.5K
- Earning Date
- WFF 01-01-0001
- TCRX 08-11-2025
- Dividend Yield
- WFF N/A
- TCRX N/A
- EPS Growth
- WFF N/A
- TCRX N/A
- EPS
- WFF 0.00
- TCRX N/A
- Revenue
- WFF $4,572,290.00
- TCRX $4,421,000.00
- Revenue This Year
- WFF N/A
- TCRX $159.20
- Revenue Next Year
- WFF N/A
- TCRX N/A
- P/E Ratio
- WFF $3,027.91
- TCRX N/A
- Revenue Growth
- WFF N/A
- TCRX N/A
- 52 Week Low
- WFF $3.20
- TCRX $1.02
- 52 Week High
- WFF $16.84
- TCRX $7.89
- Technical
- Relative Strength Index (RSI)
- WFF N/A
- TCRX 58.35
- Support Level
- WFF N/A
- TCRX $1.39
- Resistance Level
- WFF N/A
- TCRX $1.61
- Average True Range (ATR)
- WFF 0.00
- TCRX 0.15
- MACD
- WFF 0.00
- TCRX -0.01
- Stochastic Oscillator
- WFF 0.00
- TCRX 60.54
About WFF WF Holding Limited Ordinary Shares
WF Holding Ltd is a manufacturer of FRP products based in Malaysia. It has been providing high-quality and durable FRP products to various industries, including, among others, chemical processing, water and wastewater treatment, and power generation. Its products range from tanks, pipes, ducts, gratings and other custom-made FRP products. The company uses advanced production technology and equipment and has obtained various certifications. Its manufacturing capabilities allow the company to design and fabricate products that meet the specific needs of its clients, ensuring high-quality and reliable performance.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.